Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin

[Abstract.] We investigated the factors associated with fatty liver remission via treatment with ipragliflozin. The analysis was obtained from our multi-center prospective observational study, including 200 Japanese patients with type 2 diabetes treated with ipragliflozin (50mg/day) for 24 weeks. Th...

Full description

Saved in:
Bibliographic Details
Published in:ENDOCRINE JOURNAL 2019, Vol.66 (11), p.995-1000
Main Authors: Yuki Yamauchi, Akinobu Nakamura, Kiyohiko Takahashi, Takahiro Takase, Chiho Yamamoto, Isao Yokota, Tatsuya Atsumi, Hideaki Miyoshi
Format: Article
Language:Japanese
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Abstract.] We investigated the factors associated with fatty liver remission via treatment with ipragliflozin. The analysis was obtained from our multi-center prospective observational study, including 200 Japanese patients with type 2 diabetes treated with ipragliflozin (50mg/day) for 24 weeks. The extent of fatty liver was estimated using a fatty liver index (FLI). Based on the FLI after the treatment with ipragliflozin, patients were classified into remission group (FLI-30). After treatment with ipragliflozin for 24 weeks, FLI significantly improved from 64.5+-21.6 to 51.9+-26.5 (p
ISSN:0918-8959